Date published: 2025-10-18

1-800-457-3801

SCBT Portrait Logo
Seach Input

SCH 900776 (CAS 891494-63-6)

0.0(0)
Write a reviewAsk a question

Alternate Names:
; 6-Bromo-3-(1-methyl-1H-pyrazol-4-yl)-5-(3R)-3-piperidinylpyrazolo[1,5-a]pyrimidin-7-amineMK-8776
Application:
SCH 900776 is a potent and functionally selective inhibitor targeting Chk1, Cdk2, and Chk2
CAS Number:
891494-63-6
Purity:
≥98%
Molecular Weight:
376.25
Molecular Formula:
C15H18BrN7
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.

QUICK LINKS

SCH 900776 is a potent and functionally selective inhibitor targeting Chk1 (cell cycle checkpoint kinase 1) (IC50 = 3 nM), Cdk2 (IC50 = 0.16 muM), and Chk2 (IC50 = 1.5 muM). Chk1 is an essential serine/threonine kinase which responds to DNA damage and stalls DNA replication, Chk1 is also essential for maintenance of replication fork viability during exposure to DNA antimetabolites. SCH 900776 is a weak inhibitor of CDK2.


SCH 900776 (CAS 891494-63-6) References

  1. Targeting the replication checkpoint using SCH 900776, a potent and functionally selective CHK1 inhibitor identified via high content screening.  |  Guzi, TJ., et al. 2011. Mol Cancer Ther. 10: 591-602. PMID: 21321066
  2. Effects of selective checkpoint kinase 1 inhibition on cytarabine cytotoxicity in acute myelogenous leukemia cells in vitro.  |  Schenk, EL., et al. 2012. Clin Cancer Res. 18: 5364-73. PMID: 22869869
  3. Phase I and pharmacologic trial of cytosine arabinoside with the selective checkpoint 1 inhibitor Sch 900776 in refractory acute leukemias.  |  Karp, JE., et al. 2012. Clin Cancer Res. 18: 6723-31. PMID: 23092873
  4. MK-8776, a novel chk1 kinase inhibitor, radiosensitizes p53-defective human tumor cells.  |  Bridges, KA., et al. 2016. Oncotarget. 7: 71660-71672. PMID: 27690219
  5. Chk1 inhibitors overcome imatinib resistance in chronic myeloid leukemia cells.  |  Lei, H., et al. 2018. Leuk Res. 64: 17-23. PMID: 29149649
  6. Chk1 inhibitor SCH 900776 enhances the antitumor activity of MLN4924 on pancreatic cancer.  |  Li, JA., et al. 2018. Cell Cycle. 17: 191-199. PMID: 29157102
  7. Targeting acute myeloid leukemia CD34+ stem/progenitor cells with small molecule inhibitor MK-8776.  |  Lei, H., et al. 2018. Leuk Res. 72: 71-73. PMID: 30103203
  8. Effect of CHK1 Inhibition on CPX-351 Cytotoxicity in vitro and ex vivo.  |  Vincelette, ND., et al. 2019. Sci Rep. 9: 3617. PMID: 30837643
  9. Chk1 Inhibitor MK-8776 Restores the Sensitivity of Chemotherapeutics in P-glycoprotein Overexpressing Cancer Cells.  |  Cui, Q., et al. 2019. Int J Mol Sci. 20: PMID: 31443367
  10. Phosphoproteomics Analysis Reveals a Potential Role of CHK1 in Regulation of Innate Immunity through IRF3.  |  Chen, Z., et al. 2020. J Proteome Res. 19: 2264-2277. PMID: 32314919
  11. Comparative Activity and Off-Target Effects in Cells of the CHK1 Inhibitors MK-8776, SRA737, and LY2606368.  |  Ditano, JP. and Eastman, A. 2021. ACS Pharmacol Transl Sci. 4: 730-743. PMID: 33860197
  12. Inhibition of checkpoint kinase 1 potentiates anticancer activity of gemcitabine in bladder cancer cells.  |  Isono, M., et al. 2021. Sci Rep. 11: 10181. PMID: 33986399
  13. Radiation-Induced Autophagy in Human Pancreatic Cancer Cells is Critically Dependent on G2 Checkpoint Activation: A Mechanism of Radioresistance in Pancreatic Cancer.  |  Suzuki, M., et al. 2021. Int J Radiat Oncol Biol Phys. 111: 260-271. PMID: 34112559
  14. Chk1 inhibition-induced BRCAness synergizes with olaparib in p53-deficient cancer cells.  |  Zhao, Y., et al. 2023. Cell Cycle. 22: 200-212. PMID: 35959961
  15. Prognostic implication of heterogeneity and trajectory progression induced by enzalutamide in prostate cancer.  |  Feng, Y., et al. 2023. Front Endocrinol (Lausanne). 14: 1148898. PMID: 37008945

Ordering Information

Product NameCatalog #UNITPriceQtyFAVORITES

SCH 900776, 5 mg

sc-364611
5 mg
$255.00

SCH 900776, 10 mg

sc-364611A
10 mg
$338.00